R. Itzler

David C Hoaglin, Joseph C Cappelleri, Neil Hawkins, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Conducting Indirect Treatment Comparison and Network Meta-analysis Studies : Report of the ISPOR Task Force on Indirect Treatment Comparisons — Part 2

D. Hoaglin, J. Cappelleri, J. Jansen, 2010 .

Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.

Joseph C Cappelleri, Rachael Fleurence, Neil Hawkins, 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

The incidence of herpes zoster in a United States administrative database

R. Itzler, J. Pellissier, P. Saddier, 2005, Journal of General Internal Medicine.

Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.

R. Itzler, J. Pellissier, R. Insinga, 2007, PharmacoEconomics.

countries: The case of Mexico

J. Gutiérrez, R. Itzler, S. Bertozzi, 2008 .

Healthy-days time equivalents for outcomes of acute rotavirus infections.

F. Johnson, A. Hauber, E. Walter, 2011, Vaccine.

Severity of Acute GVHD and Associated Healthcare Resource Utilization, Cost and Outcomes.

R. Salloum, J. Wingard, R. Itzler, 2021, Transplantation and cellular therapy.

Cost-effectiveness of a pentavalent human–bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan

J. Cook, R. Itzler, A. E. El Khoury, 2011, Journal of medical economics.

Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries).

G. Koch, T. Vesikari, M. Santosham, 2007, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Safety and Efficacy of the Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine in Healthy Premature Infants

Penny M Heaton, Zoe M Rodriguez, Michelle G. Goveia, 2007, The Pediatric infectious disease journal.

Severity of Acute GVHD and Associated Healthcare Resource Utilization, Cost and Outcomes.

R. Salloum, J. Wingard, R. Itzler, 2021, Transplantation and cellular therapy.

Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)

G. Koch, P. van Damme, D. Matson, 2010, BMC pediatrics.

Efficacy of the pentavalent rotavirus vaccine, RotaTeq® (RV5), between doses of a 3-dose series and with less than 3 doses (incomplete regimen)

T. Vesikari, D. Matson, Penny M Heaton, 2011, Human vaccines.

Burden of rotavirus hospitalisations in young children in three paediatric hospitals in the United States determined by active surveillance compared to standard indirect methods

D. Bernstein, R. Ward, P. Azimi, 2012, Journal of paediatrics and child health.